Literature DB >> 34170459

Inherited Genetic Susceptibility to Nonimmunosuppressed Epstein-Barr Virus-associated T/NK-cell Lymphoproliferative Diseases in Chinese Patients.

Yu-Qi Guan1, Ke-Feng Shen1, Li Yang1, Hao-Dong Cai1, Mei-Lan Zhang1, Jia-Chen Wang1, Xiao-Lu Long1, Jie Xiong1, Jia Gu1, Pei-Ling Zhang1, Min Xiao2, Wei Zhang3, Jian-Feng Zhou1.   

Abstract

Epstein-Barr virus (EBV) T/NK-cell lymphoproliferative diseases are characterized by clonal expansion of EBV-infected T or NK cells, including chronic active EBV infection of T/NK-cell type (CAEBV+T/NK), EBV-associated hemophagocytic lymphohistiocytosis (EBV+HLH), extranodal NK/T-cell lymphoma of nasal type (ENKTL), and aggressive NK-cell leukemia (ANKL). However, the role of inherited genetic variants to EBV+T/NK-LPDs susceptibility is still unknown. A total of 171 nonimmunosuppressed patients with EBV+T/NK-LPDs and 104 healthy donors were retrospectively collected and a targeted sequencing study covering 15 genes associated with lymphocyte cytotoxicity was performed. The 94 gene variants, mostly located in UNC13D, LYST, ITK, and PRF1 genes were detected, and mutations covered 28/50 (56.00%) of CAEBV-T/NK, 31/51 (60.78%) of EBV+HLH, 13/28 (46.42%) of ENKTL, and 13/48 (27.09%) of ANKL. Most mutations represented monoallelic and missense. Three-year overall survival rate of patients with CAEBV-T/NK and EBV+HLH was significantly lower in patients with germline mutations than in those without germline mutations (P=0.0284, P=0.0137). Our study provided novel insights into understanding a spectrum of nonimmunosuppressed EBV+T/NK-LPDs with respect to genetic defects associated with lymphocyte cytotoxicity and reminded us that the gene sequencing may be an auxiliary test for diagnosis and risk stratification of EBV+T/NK-LPDs.
© 2021. The Author(s).

Entities:  

Keywords:  EBV-associated T/NK-cell lymphoproliferative disease; gene sequencing; germline mutation; hemophagocytic lymphohistiocytosis; lymphocyte cytotoxicity; primary immunodeficiencies

Mesh:

Substances:

Year:  2021        PMID: 34170459     DOI: 10.1007/s11596-021-2375-5

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  2 in total

1.  Aggressive natural killer cell leukemia: clinical features and treatment outcome.

Authors:  Seo-Young Song; Won Seog Kim; Young-Hyeh Ko; Kihyun Kim; Mark H Lee; Keunchil Park
Journal:  Haematologica       Date:  2002-12       Impact factor: 9.941

Review 2.  Epstein-Barr virus-associated lymphoid malignancies: the expanding spectrum of hematopoietic neoplasms.

Authors:  Hiroshi Kimura; Jun-ichi Kawada; Yoshinori Ito
Journal:  Nagoya J Med Sci       Date:  2013-08       Impact factor: 1.131

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.